[HTML][HTML] High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine

LA McNamara - MMWR. Morbidity and mortality weekly report, 2017 - cdc.gov
LA McNamara
MMWR. Morbidity and mortality weekly report, 2017cdc.gov
Eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is
associated with a 1,000-fold to 2,000-fold increased incidence of meningococcal disease
among persons receiving the drug. The Food and Drug Administration (FDA)–approved
prescribing information includes a boxed warning regarding increased risk for
meningococcal disease in eculizumab recipients. The Advisory Committee on Immunization
Practices recommends both MenACWY and MenB vaccination for patients taking …
Eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a 1,000-fold to 2,000-fold increased incidence of meningococcal disease among persons receiving the drug. The Food and Drug Administration (FDA)–approved prescribing information includes a boxed warning regarding increased risk for meningococcal disease in eculizumab recipients. The Advisory Committee on Immunization Practices recommends both MenACWY and MenB vaccination for patients taking eculizumab.
cdc.gov